


CLAIMS

A compound of the formula



- 5 where Q is C=NH, C=CH₂, C=S, C=O, SO or SO₂;
 A is CH, CH₂, C(C₁-C₈)alkyl, CH(C₁-C₆)alkyl, C(CF₃) or CH(CF₃), with the proviso that
 when B is present, A must be either CH, C(C₁-C₈)alkyl or C(CF₃);
 B is absent or is methylene or ethylene;
 each of Y and Z is N or CH, with the proviso that Y and Z can not both be N;
 10 G is NH(CH₂)_q, S(CH₂)_q or O(CH₂)_q, wherein q is zero or one;
 with the proviso that when q is zero, G is NH₂, SH or OH;
 W is a one carbon linking group (i.e., methylene) or a saturated or unsaturated two or
 three carbon linking group, wherein each of the foregoing W groups can optionally be
 substituted with one substituent R⁷ or two substituents R⁷ and R⁶, or W is a one carbon linking
 5 group that forms, together with a 2, 3, 4 or 5 carbon chain, a 3, 4, 5 or 6 membered spiro ring,
 respectively;
 or W is a saturated two carbon chain linking group that forms, together with a
 separate 1, 2 or 3 carbon chain, a fused 3, 4 or 5 membered ring, respectively;
 or W is a saturated two carbon chain linking group, wherein one of the two carbons in
 the chain forms, together with a separate 2, 3, 4 or 5 carbon chain, a 3, 4, 5 or 6 membered
 20 spiro ring, respectively;
 p is zero, one or two;
 R³ is selected from hydrogen, COR⁹, CO₂R⁹, optionally substituted phenyl, optionally
 substituted heterocyclic rings, and optionally substituted (C₁-C₈)alkyl wherein one of the CH₂
 25 groups of said (C₁-C₈) alkyl may optionally be replaced with a sulfur, oxygen or carbonyl
 group and wherein said (C₁-C₈)alkyl can optionally be substituted with from one to three
 substituents, preferably with zero substituents or one substituent, independently selected from
 hydroxy, oxo, phenyl-(C₁-C₃)alkoxy, phenyl, cyano, halo, optionally substituted heterocyclic
 rings, NR⁹COR¹⁰, NR⁹CO₂R¹⁰, CONR⁹R¹⁰, COR⁹, CO₂R⁹, NR⁹R¹⁰, and (C₁-C₆)alkoxy
 30 optionally substituted with from one to seven fluorine atoms, preferably with from zero to three
 fluorine atoms;

Express No./No. EF321679215US

C1
cont

and wherein the heterocyclic rings of R^3 and the heterocyclic ring substituents on the alkyl groups of R^3 are selected, independently, from 3 to 7 membered saturated or unsaturated monocyclic rings containing from 1 to 4 ring heteroatoms, and 8 to 12 membered saturated or unsaturated bicyclic rings containing from 1 to 4 ring heteroatoms, wherein said heteroatoms are selected, independently, from oxygen, nitrogen and sulfur, with the proviso that there can not be two adjacent ring oxygen atoms or two adjacent ring sulfur atoms in either the monocyclic or bicyclic heterocyclic rings, and with the proviso that heterocyclic rings formed from NR^9R^{10} or $CONR^9R^{10}$ must contain at least one nitrogen atom;

and wherein the heterocyclic rings of R^3 and the heterocyclic ring substituents on the alkyl groups of R^3 can optionally be substituted with one or more substituents, preferably with zero, one or two substituents, independently selected from oxo, hydroxy, thioxo, halo, cyano, phenyl, $(CH_2)_mNR^9R^{10}$, NR^9COR^{10} , $(CH_2)_mOR^9$, wherein m is zero, one or two, and (C_1-C_6) alkyl optionally substituted with one or more substituents, preferably with from zero to two substituents, independently selected from halo, CF_3 , methoxy and phenyl;

and wherein the phenyl groups of R^3 and the phenyl substituents in the alkyl groups of R^3 can optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from the group consisting of halo, cyano, nitro, CF_3 , $(CH_2)_mNR^9R^{10}$, wherein m is zero, one or two, NR^9COR^{10} , $NR^9CO_2R^{10}$, $CONR^9R^{10}$, $CO_2NR^9R^{10}$, COR^9 , CO_2R^9 , (C_1-C_6) alkyl optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, (C_1-C_6) alkoxy optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, and (C_2-C_6) alkenyl optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms;

each of R^1 , R^2 , R^{11} , R^{12} and R^{13} are selected, independently, from hydrogen and (C_1-C_6) alkyl optionally substituted with one or more substituents, preferably with zero, one or two substituents, that are selected, independently, from hydroxy, oxo, (C_1-C_6) alkoxy and cyano;

or R^1 and R^2 , together with the carbon atoms to which they are attached, or R^2 and R^3 , together with the carbon and nitrogen to which they are attached, respectively, form a 5 or 6 membered saturated heterocyclic ring containing one or two heteroatoms that are selected, independently, from nitrogen, oxygen and sulfur, with the proviso that said ring can not contain two adjacent oxygen atoms or two adjacent sulfur atoms; or R^1 and R^2 , together with the carbons to which they are attached, form a 5 or 6 membered, saturated or unsaturated carbocyclic ring, and wherein said heterocyclic and carbocyclic rings formed by R^1 and R^2 or by R^2 and R^3 can be substituted with one or more substituents, preferably with zero substituents or one substituent, independently selected from halo, oxo, NR^9R^{10} , (C_1-C_6) alkyl optionally substituted with from one to seven fluorine atoms, preferably with from zero

to three fluorine atoms, and (C₁-C₆)alkoxy optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms;

or R¹² and R¹³, together with the carbon atoms to which they are attached, form a 5 or 6 membered saturated heterocyclic ring containing one or two heteroatoms that are selected, independently, from nitrogen, oxygen and sulfur, with the proviso that said ring can not contain two adjacent oxygen atoms or two adjacent sulfur atoms, or R¹² and R¹³, together with the carbons to which they are attached, form a 5 or 6 membered, saturated or unsaturated carbocyclic ring, and wherein said heterocyclic and carbocyclic rings formed by R¹² and R¹³ can be substituted with one or more substituents, preferably with zero substituents or one substituent, independently selected from NR⁹R¹⁰, halo, phenyl-S-, phenyl-SO-, phenyl-SO₂-, oxo, (C₁-C₆)alkoxy optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, and (C₁-C₆)alkyl optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms;

with the proviso that no more than one of R¹ and R², R² and R³, and R¹² and R¹³ can form a ring;

R⁴ is selected from phenyl, 2-, 3- or 4-pyridyl, 2- or 3-thienyl, and pyrimidyl, wherein R⁴ can be optionally substituted with one or more substituents, preferably with zero or one substituent, selected, independently, from halo, (C₁-C₆)alkyl optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, (C₁-C₆)alkoxy optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, and (C₂-C₆) alkenyl optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms;

R⁵ and R⁸ are selected, independently, from hydrogen, -SO(C₁-C₆)alkyl, -SO₂-(C₁-C₆)alkyl, -SO-aryl, -SO₂-aryl, CF₃, halo, phenyl, phenyl-(C₁-C₂)alkyl, hydroxy, aryloxy, heteroaryloxy, pyridyl, tetrazolyl, oxazolyl, thiazolyl, (C₁-C₆)alkoxy optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, (C₁-C₆)alkyl optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, and (C₁-C₆)alkyl substituted with one or more substituents, preferably with from zero to two substituents selected, independently, from hydroxy, oxo, (C₁-C₆)alkoxy, phenyl-(C₁-C₃)alkoxy, phenyl, cyano, chloro, bromo, iodo, NR⁹R¹⁰, NR⁹COR¹⁰, NR⁹CO₂R¹⁰, CONR⁹R¹⁰, COR⁹ and CO₂R⁹;

R⁶ and R⁷ are selected, independently, from -SO(C₁-C₆)alkyl, -SO₂-(C₁-C₆)alkyl, -SO-aryl, -SO₂-aryl, CF₃, halo, phenyl, phenyl-(C₁-C₂)alkyl, hydroxy, aryloxy, heteroaryloxy, pyridyl, tetrazolyl, oxazolyl, thiazolyl, (C₁-C₆)alkoxy optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, (C₁-C₆)alkyl optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, and (C₁-C₆)alkyl substituted with one or more substituents, preferably with from zero to

C1
cont

two substituents selected, independently, from hydroxy, oxo, (C₁-C₆)alkoxy, phenyl-(C₁-C₃)alkoxy, phenyl, cyano, chloro, bromo, iodo, NR⁹R¹⁰, NR⁹COR¹⁰, NR⁹CO₂R¹⁰, CONR⁹R¹⁰, COR⁹ and CO₂R⁹;

each R⁹ and each R¹⁰ is selected, independently, from hydrogen, (C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, phenyl and CF₃;


or R⁹ and R¹⁰, when R³ is NR⁹R¹⁰ or CONR⁹R¹⁰, can form, together with the nitrogen to which they are attached, an optionally substituted heterocyclic ring that contains at least one nitrogen atom;

and wherein the phenyl groups in the definition of R⁵, R⁶, R⁷ and R⁸ and the phenyl moiety of phenyl (C₁-C₂)alkyl in the definition of R⁵, R⁶, R⁷ and R⁸ can optionally be substituted with one or more substituents, preferably with from zero to two substituents, that are selected, independently, from halo, hydroxy, (C₁-C₆)alkoxy optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, and (C₁-C₆)alkyl optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms;


with the proviso that: (a) R⁸ can not be halo, hydroxy, cyano, aryloxy, heteroaryloxy, substituted or unsubstituted (C₁-C₆)alkoxy or methyl substituted with from 1-3 fluorine atoms; and (b) when Q is C=O or C=S, and Y and Z are both carbon, and W is a methylene, ethylene or propylene group that is optionally substituted with (C₁-C₆)alkyl or fluoro substituted (C₁-C₆)alkyl, and all of R¹, R², R¹¹, R¹² and R¹³ are hydrogen, and R⁵, R⁶, R⁷, and R⁸ are selected from hydrogen, halo, (C₁-C₆) alkyl optionally substituted with from 1 to 7 fluorine atoms, (C₁-C₆) alkoxy optionally substituted with from 1 to 7 fluorine atoms, then R³ can not be hydrogen;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, wherein R³ is an optionally substituted heterocyclic ring, or an alkyl group substituted with an optionally substituted heterocyclic ring, wherein said heterocyclic ring is selected from the following: pyrimidinyl, benzoxazolyl, 2,3-dihydro-3-oxobenzisofurazolidin-2-yl, morpholin-1-yl, thiomorpholin-1-yl, benzofuranyl, benzothienyl, indolyl, isoindolyl, isoquinolinyl, furyl, pyridyl, isothiazolyl, oxazolyl, triazolyl, tetrazolyl, quinolyl, thiazolyl, and thienyl, and groups of the formulas



and



wherein B² and D are selected from carbon, oxygen and nitrogen, and at least one of B² and D is other than carbon; E is carbon or nitrogen; q is an integer from 1 to 5; any one of the carbon atoms of said (CH₂)_q and (CH₂)_{q+1} may be optionally substituted with (C₁-C₆)alkyl

or (C₁-C₆) spiroalkyl; and either any one pair of the carbon atoms of said (CH₂)_q and (CH₂)_{q+1} may be bridged by a one or two carbon atom linkage, or any one pair of adjacent carbon atoms of said (CH₂)_q and (CH₂)_{q+1} may form, together with from one to three carbon atoms that are not members of the carbonyl containing ring, a (C₃-C₅) fused carbocyclic ring.

- 5 3. A compound according to claim 1, wherein B is absent and A is CH₂.
4. A compound according to claim 1, wherein Q is a carbonyl group.
5. A compound according to claim 1, wherein Y and Z are both CH.
6. A compound according to claim 1, wherein B is ethylene, A is CH and G is
 NHCH₂.
- 10 7. A compound according to claim 1, wherein B is ethylene, A is CH and G is
 SCH₂.
8. A compound according to claim 1, wherein R³ is hydrogen.
9. A compound according to claim 1, wherein R³ is CO₂R⁹.
10. A compound according to claim 1, wherein B is absent, G is NH and A is
15 CH₂.
11. A compound according to claim 1, wherein W is ethylene.
12. A compound according to claim 1, wherein R⁴ is phenyl.
13. A compound according to claim 1, wherein R⁴ is phenyl and R⁸ is hydrogen.
14. A compound according to claim 1, wherein p is one.
- 20 15. A compound according to claim 1, wherein R² is (C₁-C₆)alkyl.
16. A compound according to claim 1, wherein R² is (C₁-C₆)alkyl wherein the
 stereochemical configuration at the chiral carbon to which R² is attached is "S".
17. A compound according to claim 1, wherein R⁴ is 2-, 3- or 4-pyridyl.
18. A compound according to claim 1, wherein R² and R¹² are selected,
25 independently, from methyl and ethyl.
19. A compound according to claim 1, wherein Y is CH.
20. A compound according to claim 3, wherein Q is a carbonyl group.
21. A compound according to claim 1, wherein Y is CH and Z is nitrogen.
22. A compound according to claim 2, wherein Q is a carbonyl group.
- 30 23. A compound according to claim 2, wherein Y is CH and Z is CH.
24. A compound according to claim 1, wherein Q is C=O and W is methylene
 optionally substituted with one or two substituents independently selected from (C₁-C₆)alkyl
 and CF₃.
25. A compound according to claim 1, wherein Q is C=O and W is ethylene
35 optionally substituted with one or two substituents independently selected from (C₁-C₆)alkyl
 and CF₃.
26. A compound according to claim 1, wherein Q is SO.

27. A compound according to claim 1, wherein Q is SO₂.
28. A compound according to claim 1, wherein Y is nitrogen and Z is CH.
29. A compound according to claim 1, wherein Q is C=S.
30. A compound according to claim 3 wherein R⁸ is hydrogen.
- 5 31. A compound according to claim 1 wherein R³ is a heterocyclic ring.
32. A compound according to claim 1 wherein R³ is an alkyl group substituted with a heterocyclic ring.
33. A compound according to claim 1 wherein R³ is an alkyl group substituted with a heterocyclic ring selected from imidazolyl, 5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl, benzoxazol-2-yl, and 5-oxo-pyrrolidin-2-yl.
- 10 34. A compound according to claim 1 wherein R⁴ is optionally substituted pyridyl.
35. A compound according to claim 1 wherein R² and R¹² are selected from (C₁-C₃)alkyl.
36. A compound according to claim 32 wherein Q is a carbonyl group.
- 15 37. A compound according to claim 2 wherein B is ethylene, A is CH and G is NHCH₂.
38. A compound according to claim 2 wherein B is ethylene, A is CH and G is SCH₂.
39. A compound according to claim 3 wherein R³ is hydrogen.
- 20 40. A compound according to claim 3 wherein B is ethylene, A is CH and G is NHCH₂.
41. A compound according to claim 3 wherein R³ is CO₂R⁹.
42. A compound according to claim 3 wherein G is NH.
43. A compound according to claim 3 wherein W is ethylene.
- 25 44. A compound according to claim 3 wherein R⁴ is phenyl.
45. A compound according to claim 3 wherein R⁴ is phenyl and R⁸ is hydrogen.
46. A compound according to claim 3 wherein p is one.
47. A compound according to claim 3 wherein R² is (C₁-C₆)alkyl.
48. A compound according to claim 3 wherein R² is (C₁-C₆)alkyl wherein the stereochemical configuration at the chiral carbon to which R² is attached is "S".
- 30 49. A compound according to claim 3 wherein R⁴ is 2-, 3- or 4-pyridyl.
50. A compound according to claim 3 wherein R² and R¹² are selected, independently, from hydrogen, methyl, ethyl and propyl.
51. A compound according to claim 3 wherein both R² and R¹² are other than hydrogen.
- 35 52. A compound according to claim 3 wherein Y is CH.
53. A compound according to claim 3 wherein Y is CH and Z is CH.

54. A compound according to claim 2 wherein Y is CH and Z is nitrogen.

55. A compound according to claim 3 wherein Q is C=O and W is methylene optionally substituted with one or two substituents independently selected from (C₁-C₆)alkyl and CF₃.

5 56. A compound according to claim 3 wherein Q is C=O and W is ethylene optionally substituted with one or two substituents independently selected from (C₁-C₆)alkyl and CF₃.

57. A compound according to claim 3 wherein Q is SO.

58. A compound that is selected from isomers and mixtures of isomers of the
10 following compounds, wherein said isomers or mixtures of isomers have the stereochemistry depicted in structural formula I:

7-[(1-Dimethylaminoacetyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one;

15 6-Methoxy-1-methyl-7-[(2-phenyl-1-(pyridin-2-yl-acetyl)-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-1-methyl-7-[(2-phenyl-1-(pyridin-3-yl-acetyl)-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-1-methyl-7-[(2-phenyl-1-(pyridin-4-yl-acetyl)-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

20 6-Cyclopropoxy-1-methyl-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

(5-Chloro-2-methoxy-benzyl)-(2-phenyl-octahydro-cyclopenta[b]pyrrol-3-yl)-amine;

6-Methoxy-1-methyl-7-[(1-[1,2,4]oxadiazol-3-ylmethyl-2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

25 7-[(1-(Imidazol-1-yl-acetyl)-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one;

1-[3-(2-Methoxy-5-trifluoromethoxy-benzylamino)-2-phenyl-piperidin-1-yl]-2-pyridin-2-yl-ethanone;

30 1-[3-(2-Methoxy-5-trifluoromethoxy-benzylamino)-2-phenyl-piperidin-1-yl]-2-pyridin-3-yl-ethanone;

1-[3-(2-Methoxy-5-trifluoromethoxy-benzylamino)-2-phenyl-piperidin-1-yl]-2-pyridin-4-yl-ethanone;

2-Imidazol-1-yl-1-[3-(2-methoxy-5-trifluoromethoxy-benzylamino)-2-phenyl-piperidin-1-yl]-ethanone;

35 2-Dimethylamino-1-[3-(2-methoxy-5-trifluoromethoxy-benzylamino)-2-phenyl-piperidin-1-yl]-ethanone

3-(2-Benzyloxy-5-trifluoromethoxy-phenyl)-6-phenyl-1-oxa-7-aza-spiro[4.5]decane;

1-[3-(2-Methoxy-5-trifluoromethoxy-benzylamino)-2-phenyl-piperidin-1-yl]-2-pyrrolidin-1-yl-ethanone;

(2-Methoxy-5-trifluoromethoxy-benzyl)-(1-[1,2,4]oxadiazol-3-ylmethyl-2-phenyl-piperidin-3-yl)-amine;

5 7-[[2-(4-Fluoro-phenyl)-piperidin-3-ylamino]-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one;

[1-(2-Imidazol-1-yl-ethyl)-2-phenyl-piperidin-3-yl]-(2-methoxy-5-trifluoromethoxy-benzyl)-amine;

10 7-[[1-(2-Dimethylamino-ethyl)-2-phenyl-piperidin-3-ylamino]-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one;

(5-Chloro-2-ethoxy-pyridin-3-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;

(5-Chloro-2-methoxy-pyridin-3-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;

Dibenzofuran-2-ylmethyl-(2-phenyl-piperidin-3-yl)-amine;

[3-(Indan-2-yloxy)-4-methoxy-benzyl]-(2-phenyl-piperidin-3-yl)-amine;

15 6-[(2-Phenyl-piperidin-3-ylamino)-methyl]-chroman-4-one;

(5-Methyl-benzo[b]thiophen-3-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;

(2,2-Dimethyl-chroman-6-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;

(1H-Benzimidazol-5-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;

20 1-[2-[(2-Phenyl-piperidin-3-ylamino)-methyl]-phenyl]-pyrrolidin-2-one;

(2-Phenyl-piperidin-3-yl)-[3-(pyridin-2-yloxy)-benzyl]-amine

[3-(4-Methoxy-phenoxy)-benzyl]-(2-phenyl-piperidin-3-yl)-amine;

(4-Phenoxy-benzyl)-(2-phenyl-piperidin-3-yl)-amine;

(2-Phenyl-piperidin-3-yl)-thiophen-2-ylmethyl-amine;

Furan-2-ylmethyl-(2-phenyl-piperidin-3-yl)-amine;

25 (5-Methyl-furan-2-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;

(3-Methyl-thiophen-2-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;

(2-Phenyl-piperidin-3-yl)-thiophen-3-ylmethyl-amine;

(3-Methyl-benzo[b]thiophen-2-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;

Benzofuran-2-ylmethyl-(2-phenyl-piperidin-3-yl)-amine;

30 (5-Ethyl-furan-2-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;

(5-Chloro-3-methyl-1-phenyl-1H-pyrazol-4-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;

6-Methoxy-7-[[1-(2-methoxy-ethyl)-2-phenyl-piperidin-3-ylamino]-methyl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

(5-Methyl-3-phenyl-isoxazol-4-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;

35 (3-Phenoxy-benzyl)-(2-phenyl-piperidin-3-yl)-amine;

Furan-3-ylmethyl-(2-phenyl-piperidin-3-yl)-amine;

(3,5-Dimethyl-1-phenyl-1H-pyrazol-4-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;

C2
cont

- 5 (5,7-Dimethoxy-1H-indol-4-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;
- (5-Methoxy-1H-indol-3-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;
- (4-Oxy-quinoxalin-2-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;
- (2-Phenyl-piperidin-3-yl)-quinoxalin-2-ylmethyl-amine;
- 7-[[1-(2,3-Dihydroxy-propyl)-2-phenyl-piperidin-3-ylamino]-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one;
- (2-Methoxy-5-trifluoromethoxy-benzyl)-[2-phenyl-1-(2-pyrrolidin-1-yl-ethyl)-piperidin-3-yl]-amine;
- 6-Ethoxy-1-methyl-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;
- 10 [1-(2-Dimethylamino-ethyl)-2-phenyl-piperidin-3-yl]-(2-methoxy-5-trifluoromethoxy-benzyl)-amine;
- 3-(2-Cyclopropoxy-5-trifluoromethoxy-phenyl)-6-phenyl-1-oxa-7-aza-spiro[4.5]decane;
- 15 [1-(2-Methoxy-ethyl)-2-phenyl-piperidin-3-yl]-(2-methoxy-5-trifluoromethoxy-benzyl)-amine;
- 6-Hydroxy-1-methyl-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;
- 6-Methoxy-1-methyl-7-[(2-phenyl-octahydro-cyclopenta[b]pyrrol-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;
- 20 3,4-dihydro-1H-quinolin-2-one;
- 7-[[2-(4-Fluoro-phenyl)-piperidin-3-ylamino]-methyl]-6-methoxy-3,4-dihydro-1H-quinolin-2-one;
- 6-Methoxy-1-methyl-7-(6-phenyl-1-oxa-7-aza-spiro[4.5]dec-3-yl)-3,4-dihydro-1H-quinolin-2-one;
- 25 6-Methoxy-1,3,3-trimethyl-5-[(2-phenyl-octahydro-cyclopenta[b]pyrrol-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;
- [3-Chloro-2-(4-fluoro-phenoxy)-pyridin-4-ylmethyl]-(2-phenyl-piperidin-3-yl)-amine;
- 6-Ethoxy-1,3,3-trimethyl-5-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;
- 30 6-Ethoxy-1,3,3-trimethyl-5-[(2-phenyl-octahydro-cyclopenta[b]pyrrol-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;
- 6-Isopropoxy-1,3,3-trimethyl-5-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;
- 6-Isopropoxy-1,3,3-trimethyl-5-[(2-phenyl-octahydro-cyclopenta[b]pyrrol-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;
- 35 6-Ethoxy-1,3,3-trimethyl-5-[(2-phenyl-octahydro-cyclopenta[b]pyrrol-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

C²
cont

- 6-Isopropoxy-1,3,3-trimethyl-5-[(2-phenyl-octahydro-cyclopenta[b]pyrrol-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;
- 7-Isopropoxy-1-methyl-6-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;
- 5 6-Methoxy-1-methyl-7-[(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;
- 6-Methoxy-1,3,3-trimethyl-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;
- 6-Methoxy-1,3-dimethyl-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;
- 10 6-Methoxy-1,3-dimethyl-5-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;
- 6-Methoxy-1-methyl-5-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;
- 15 5-[(1-Isopropyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1,3,3-trimethyl-1,3-dihydro-indol-2-one;
- 6-Methoxy-1-methyl-7-[(2-phenyl-1-propyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;
- 6-Methoxy-1-methyl-7-[[1-(5-methyl-3H-imidazol-4-ylmethyl)-2-phenyl-piperidin-3-ylamino]-methyl]-3,4-dihydro-1H-quinolin-2-one;
- 20 7-[[1-(1H-imidazol-4-ylmethyl)-2-phenyl-piperidin-3-ylamino]-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one;
- 7-[(1-Isopropyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one;
- 25 6-Methoxy-1,3-dimethyl-7-[(1-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;
- 5-[(1-Isopropyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1,3,3-trimethyl-1,3-dihydro-indol-2-one
- 6-Methoxy-1-methyl-7-[[1-(5-oxo-2,5-dihydro-1H-[1,2,4]triazol-3-ylmethyl)-2-phenyl-piperidin-3-ylamino]-methyl]-3,4-dihydro-1H-quinolin-2-one;
- 30 6-Methoxy-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;
- 1-Ethyl-6-methoxy-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;
- 1-Methanesulfonyl-6-methoxy-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;
- 35 6-Methoxy-1,4,4-trimethyl-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

8-Fluoro-6-methoxy-1,4,4-trimethyl-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-1-methyl-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-1,4-dimethyl-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-2-methyl-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-2H-isoquinolin-1-one;

6-Methoxy-3-methyl-5-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

6-Methoxy-1-methyl-3,3-cyclopropyl-5-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

5-Methoxy-1-methyl-3,3-cyclopropyl-6-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

6-Methoxy-1-methyl-(6-phenyl-1,7-diaza-spiro[4.5]dec-3-yl)-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-1-methyl-7-phenyl-1,7-diaza-spiro[4.5]dec-3-yl)-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-3-methyl-5-[(1-phenyl-8-aza-bicyclo[3.2.1]oct-2-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

(6-Methoxy-1-methyl-2,2-dioxo-1,2,3,4-tetrahydro-2-thiobenzo[c][1,2]thiazin-7-yl-methyl)- (2-phenyl-piperidin-3-yl)-amine;

6-Methoxy-3-methyl-5-[(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

6-Methoxy-1-methyl-7-(6-phenyl-1,7-diaza-spiro[4.5]dec-3-yl)-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-1,3,3-trimethyl-5-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one;

5-Methoxy-1,3,3-trimethyl-6-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-pyrrolo[3,2-b]pyridin-2-one;

6-Methoxy-1-methyl-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-[1,5]naphthyridin-2-one;

7-[(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one;

5-[(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1,3,3-trimethyl-1,3-dihydro-indol-2-one;

6-Methoxy-1,3,3-trimethyl-5-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one;

5-Methoxy-1,3,3-trimethyl-6-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-pyrrolo[3,2-b]pyridin-2-one;

6-Methoxy-1-methyl-7-[(2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-[1,5]naphthyridin-2-one;

6-Methoxy-1-methyl-7-[(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-[1,5]naphthyridin-2-one;

7-[(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-[1,5]naphthyridin-2-one;

6-Methoxy-1-methyl-7-[(2-phenyl-6-propyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-[1,5]naphthyridin-2-one;

6-Methoxy-3-methyl-5-[(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

6-Methoxy-1-methyl-7-(6-phenyl-1,7-diaza-spiro[4.5]dec-3-yl)-3,4-dihydro-1H-quinolin-2-one;

and pharmaceutically acceptable salts thereof.

59. A compound according to claim 1, selected from the group consisting of:

5-[(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

(1S,1aR)-5-[(2S,3S,6S)-(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

(1R,1aS)-5-[(2R,3R,6R)-(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

(1R,1aS)-5-[(2S,3S,6S)-(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

(1S,1aR)-5-[(2R,3R,6R)-(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

6-Methoxy-3-methyl-5-[(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

(1S,1aR)-6-Methoxy-3-methyl-5-[(2S,3S,6S)-(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

(1R,1aS)-6-Methoxy-3-methyl-5-[(2R,3R,6R)-(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

(1R,1aS)-6-Methoxy-3-methyl-5-[(2S,3S,6S)-(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

(1S,1aR)-6-Methoxy-3-methyl-5-[(2R,3R,6R)-(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

6-Methoxy-3-methyl-5-[(2-phenyl-6-propyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

6-Methoxy-1-methyl-7-[(2-phenyl-6-propyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

7-[(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one;

6-Methoxy-1-methyl-7-[(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

7-[(2S,3S,6S)-6-Isopropyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinoline-2-one;

7-[(6,6-Dimethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one;

7-[(2S,3S,6S)-6-Isopropyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-[1,5]naphthyridin-2-one;

5-[(5-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

6-Methoxy-3-methyl-5-[(5-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

6-Methoxy-3-methyl-5-[(2-phenyl-5-propyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

(6-Methoxy-1-methyl-2,2-dioxo-1,2,3,4-tetrahydro-2⁶-benzo[c][1,2]thiazin-7-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;

6-Methoxy-1-methyl-,3,3-spirocyclopropyl-5-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

5-Methoxy-1-methyl-,3,3-spirocyclopropyl-6-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

5-Methoxy-1-methyl-,3,3-cyclobutyl-6-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

6-Methoxy-1-methyl-,3,3-cyclopentyl-5-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

6-Methoxy-1-methyl-,3,3-cyclohexyl-5-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

(1S, 1aR)-6-Methoxy-3-methyl-5-[(1S,2S,5R)-(1-phenyl-8-aza-bicyclo[3.2.1]oct-2-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

(1R, 1aS)-6-Methoxy-3-methyl-5-[(1R,2R,5S)-(1-phenyl-8-aza-bicyclo[3.2.1]oct-2-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

(2-Methoxy-5-trifluoromethoxy-benzyl)-(1S,2S,5R) 1-phenyl-8-azabicyclo[3.2.1]oct-2-yl)-amine;

(2-Methoxy-5-trifluoromethoxy-benzyl)-(1R,2R,5S) 1-phenyl-8-azabicyclo[3.2.1]oct-2-yl)-amine;

5-Methoxy-1-methyl-3,3-cyclopropyl-6-[(1S,2S,5R)-(1-phenyl-8-azabicyclo[3.2.1]oct-2-yl)-amine)-methyl]-1,3-dihydro-indol-2-one;

(6-Methoxy-1-methyl-2,2-dioxo-1,2,3,4-tetrahydro-2⁶-benzo[c][1,2]thiazin-7-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;

and pharmaceutically acceptable salts thereof.

60. A compound according to claim 59, selected from the group consisting of:

5-[(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one monohydrochloride;

(1S,1aR)-5-[(2S,3S,6S)-(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one monohydrochloride;

(1R,1aS)-5-[(2R,3R,6R)-(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one monohydrochloride;

(1R,1aS)-5-[(2S,3S,6S)-(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one monohydrochloride;

(1S,1aR)-5-[(2R,3R,6R)-(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one monohydrochloride;

6-Methoxy-3-methyl-5-[(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one monohydrochloride;

(1S,1aR)-6-Methoxy-3-methyl-5-[(2S,3S,6S)-(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one monohydrochloride;

(1R,1aS)-6-Methoxy-3-methyl-5-[(2R,3R,6R)-(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one monohydrochloride;

(1R,1aS)-6-Methoxy-3-methyl-5-[(2S,3S,6S)-(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one monohydrochloride;

(1S,1aR)-6-Methoxy-3-methyl-5-[(2R,3R,6R)-(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one monohydrochloride;

6-Methoxy-3-methyl-5-[(2-phenyl-6-propyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one monohydrochloride;

6-Methoxy-1-methyl-7-[(2-phenyl-6-propyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one monohydrochloride;

7-[(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one monohydrochloride;

6-Methoxy-1-methyl-7-[(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one monohydrochloride;

5-[(5-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one monohydrochloride;

6-Methoxy-3-methyl-5-[(5-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one monohydrochloride; and

6-Methoxy-3-methyl-5-[(2-phenyl-5-propyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one monohydrochloride.

61. A compound according to claim 59, selected from the group consisting of:

5-[(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(D)-lactate;

(1S,1aR)-5-[(2S,3S,6S)-(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(D)-lactate;

(1R,1aS)-5-[(2R,3R,6R)-(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(D)-lactate;

(1R,1aS)-5-[(2S,3S,6S)-(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(D)-lactate;

(1S,1aR)-5-[(2R,3R,6R)-(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(D)-lactate;

6-Methoxy-3-methyl-5-[(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(D)-lactate;

(1S,1aR)-6-Methoxy-3-methyl-5-[(2S,3S,6S)-(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(D)-lactate;

(1R,1aS)-6-Methoxy-3-methyl-5-[(2R,3R,6R)-(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(D)-lactate;

(1R,1aS)-6-Methoxy-3-methyl-5-[(2S,3S,6S)-(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(D)-lactate;

(1S,1aR)-6-Methoxy-3-methyl-5-[(2R,3R,6R)-(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(D)-lactate;

6-Methoxy-3-methyl-5-[(2-phenyl-6-propyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(D)-lactate;

6-Methoxy-1-methyl-7-[(2-phenyl-6-propyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one mono-(D)-lactate;

7-[(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one mono-(D)-lactate;

6-Methoxy-1-methyl-7-[(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one mono-(D)-lactate;

5-[(5-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(D)-lactate;

6-Methoxy-3-methyl-5-[(5-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(D)-lactate; and

6-Methoxy-3-methyl-5-[(2-phenyl-5-propyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(D)-lactate.

62. A compound according to claim 59, selected from the group consisting of:

5-[(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(L)-lactate;

(1S,1aR)-5-[(2S,3S,6S)-(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(L)-lactate;

(1R,1aS)-5-[(2R,3R,6R)-(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(L)-lactate;

(1R,1aS)-5-[(2S,3S,6S)-(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(L)-lactate;

(1S,1aR)-5-[(2R,3R,6R)-(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(L)-lactate;

6-Methoxy-3-methyl-5-[(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(L)-lactate;

(1S,1aR)-6-Methoxy-3-methyl-5-[(2S,3S,6S)-(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(L)-lactate;

(1R,1aS)-6-Methoxy-3-methyl-5-[(2R,3R,6R)-(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(L)-lactate;

(1R,1aS)-6-Methoxy-3-methyl-5-[(2S,3S,6S)-(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(L)-lactate;

(1S,1aR)-6-Methoxy-3-methyl-5-[(2R,3R,6R)-(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(L)-lactate;

6-Methoxy-3-methyl-5-[(2-phenyl-6-propyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(L)-lactate;

6-Methoxy-1-methyl-7-[(2-phenyl-6-propyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one mono-(L)-lactate;

7-[(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one mono-(L)-lactate;

6-Methoxy-1-methyl-7-[(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one mono-(L)-lactate;

B1
cont
5-[(5-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(L)-lactate;

6-Methoxy-3-methyl-5-[(5-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(L)-lactate; and

5 6-Methoxy-3-methyl-5-[(2-phenyl-5-propyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one mono-(L)-lactate.

63. A compound that is selected from isomers and mixtures of isomers of the following compounds, wherein said isomers or mixtures of isomers have the stereochemistry depicted in structural formula I:

10 6-Methoxy-1-methyl-7-[(2-phenyl-6-propyl-piperidin-3-ylamino)-methyl]-3,4-dihydro-1H-quinolin-2-one;

7-[(6-Isopropyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one;

15 7-[(6-Tert-butyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one;

7-[(6-Isobutyl-2-phenyl-piperidin-3-ylamino)-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one;

7-[(1,2,3,4,5,6-Hexahydro-[2,3']bipyridinyl-3-ylamino)-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one;

20 7-[(1,2,3,4,5,6-Hexahydro-[2,4']bipyridinyl-3-ylamino)-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one;

(6-Methoxy-1-methyl-2,2-dioxo-1,2,3,4-tetrahydro-2-thiobenzo[c [1,2]thiazin-7-ylmethyl)-(2-phenyl-piperidin-3-yl)-amine;

25 6-Methoxy-3-methyl-5-[(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

6-Methoxy-1-methyl-,3,3-cyclopropyl-5-[(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

5-Methoxy-1-methyl-,3,3-cyclopropyl-6-[(1-phenyl-8-aza-bicyclo[3.2.1]oct-2-ylamino)-methyl]-1,3-dihydro-indol-2-one;

30 6-Methoxy-1-methyl-,3,3-cyclohexane-5-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

6-Methoxy-1-methyl-,3,3-cyclopentyl-5-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

35 6-Methoxy-1-methyl-,3,3-cyclopropyl-5-[(2-(-4-fluorophenyl)-piperidin-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

6-Methoxy-1-methyl-,3,3-cyclobutyl-5-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

5-Methoxy-1-methyl-,3,3-cyclobutyl-6-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

5-Methoxy-1-methyl-,3,3-cyclopropyl-6-[(6-methyl-2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-indol-2-one;

5 6-Methoxy-1,3-dimethyl-5-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

7-[(1,2,3,4,5,6-Hexahydro-[2,2']bipyridinyl-3-ylamino)-methyl]-6-methoxy-1-methyl-3,4-dihydro-1H-quinolin-2-one;

10 one;
6-[(6-Ethyl-2-phenyl-piperidin-3-ylamino)-methyl]-5-methoxy-1,1-dimethyl-indan-2-

and pharmaceutically acceptable salts thereof.

64. A method of treating a disorder or condition selected from the group consisting of mood disorders, such as depression, or more particularly, depressive disorders, for example, single episodic or recurrent major depressive disorders, dysthymic disorders, 15 depressive neurosis and neurotic depression, melancholic depression, including anorexia, weight loss, insomnia, early morning waking and psychomotor retardation, atypical depression (or reactive depression), including increased appetite, hypersomnia, psychomotor agitation or irritability, seasonal affective disorder and pediatric depression; or bipolar disorders or manic depression, for example, bipolar I disorder, bipolar II disorder and 20 cyclothymic disorder; conduct disorder and disruptive behavior disorder; anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, for example, specific animal phobias, social anxiety, social phobias, obsessive-compulsive disorder, stress disorders, including post-traumatic stress disorder and acute stress disorder, and generalized anxiety disorders; borderline personality 25 disorder; schizophrenia and other psychotic disorders, for example, schizophreniform disorders, schizoaffective disorders, delusional disorders, brief psychotic disorders, shared psychotic disorders, psychotic disorders with delusions or hallucinations, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder; mood disorders associated with psychotic disorders such as acute 30 mania and depression associated with bipolar disorder, mood disorders associated with schizophrenia; behavioral disturbances associated with mental retardation, autistic disorder, and conduct disorder in a mammal, including a human, comprising administering to said mammal an amount of a compound according to claim 1 that is effective in treating such condition or disorder.

35 65. A method of treating a disorder or condition selected from the group consisting of delerium, dementia, and amnestic and other cognitive or neurodegenerative disorders, such as Parkinson's disease (PD), Huntington's disease (HD), Alzheimer's disease,

senile dementia, dementia of the Alzheimer's type, memory disorder, vascular dementia, and other dementias, for example, due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple aetiologies; movement disorders such as akinesias, dyskinesias, including familial paroxysmal dyskinesias, spasticities, Tourette's syndrome, Scott syndrome, PALSYS and akinetic-rigid syndrome; extra-pyramidal movement disorders such as medication-induced movement disorders, for example, neuroleptic-induced Parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia and medication-induced postural tremour; substance-related disorders arising from the use of alcohol, amphetamines (or amphetamine-like substances) caffeine, cannabis, cocaine, hallucinogens, inhalants and aerosol propellants, nicotine, opioids, phenylglycidine derivatives, sedatives, hypnotics, and anxiolytics, which substance-related disorders include dependence and abuse, intoxication, withdrawal, intoxication delirium and withdrawal delirium; addictive behaviors such as gambling; epilepsy; Down's syndrome; acute pain, chronic pain and migraine; demyelinating diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS), peripheral neuropathy, for example diabetic and chemotherapy-induced-neuropathy, and postherpetic neuralgia, trigeminal neuralgia, segmental or intercostal neuralgia and other neuralgias; and cerebral vascular disorders due to acute or chronic cerebrovascular damage such as cerebral infarction, subarachnoid haemorrhage or cerebral oedema in a mammal, including a human, comprising administering to said mammal an amount of a compound according to claim 1 that is effective in treating such condition or disorder.

66. A method of treating a disorder or condition selected from the group consisting of respiratory diseases, particularly those associated with excess mucus secretion, such as chronic obstructive airways disease, bronchopneumonia, chronic bronchitis, cystic fibrosis, adult respiratory distress syndrome, and bronchospasm; inflammatory diseases such as inflammatory bowel disease, psoriasis, Reiter's syndrome, Raynaud's syndrome, anarthropathies, fibrositis, osteoarthritis, rheumatoid arthritis, psoriatic arthritis, asthma, pruritis and sunburn; human immunodeficiency virus (HIV) infections; allergies such as eczema and rhinitis, and other allergies; hypersensitivity disorders such as poison ivy; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, and the like; ophthalmic conditions associated with cell proliferation such as proliferative vitreoretinopathy; cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis in a mammal, including a human, comprising administering to said mammal an amount of a compound according to claim 1 that is effective in treating such condition or disorder.

67. A method of treating a disorder or condition selected from the group consisting of neoplasms, including breast tumours, gastric carcinomas, gastric lymphomas,

neuroganglioblastomas and small cell carcinomas such as small cell lung cancer in a mammal, including a human, comprising administering to said mammal an amount of a compound according to claim 1 that is effective in treating such condition or disorder.

68. A method of treating a disorder or condition selected from the group consisting of gastrointestinal (GI) disorders, including inflammatory gastrointestinal disorders such as inflammation bowel disease disorders, caused by *helicobacter pylori* and diseases of the GI tract such as gastritis, gastroduodenal ulcers, disorders associated with the neuronal control of viscera, ulcerative colitis, Crohn's disease, irritable bowel syndrome and emesis in a mammal, including a human, comprising administering to said mammal an amount of a compound according to claim 1 that is effective in treating such condition or disorder.

69. A method of treating a disorder or condition selected from the group consisting of stress related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome; adverse immunological reactions such as rejection of transplanted tissues and disorders related to immune enhancement or suppression such as systemic lupus erythematosus; plasma extravasation resulting from cytokine chemotherapy; disorders of bladder function such as cystitis, bladder detrusor hyper-reflexia, inflammation of the urinary tract and incontinence, including urinary urge incontinence, overactive bladder, stress incontinence and mixed incontinence; fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; blood flow disorders caused by vasodilation and vasospastic diseases such as angina and Reynaud's disease; angiogenesis; cardiovascular disorders; eating disorders, such as anorexia nervosa and bulimia nervosa; attention deficit hyperactivity disorder; chronic fatigue syndrome; sexual dysfunctions including premature ejaculation and male erectile dysfunction; premenstrual syndrome and premenstrual dysphoric disorder; fibromyalgia; and rheumatic diseases such as fibrositis in a mammal, including a human, comprising administering to said mammal an amount of a compound according to claim 1 that is effective in treating such condition or disorder.

70. A pharmaceutical composition for treating a disorder or condition selected from the group consisting of mood disorders, such as depression, or more particularly, depressive disorders, for example, single episodic or recurrent major depressive disorders, dysthymic disorders, depressive neurosis and neurotic depression, melancholic depression, including anorexia, weight loss, insomnia, early morning waking and psychomotor retardation, atypical depression (or reactive depression), including increased appetite, hypersomnia, psychomotor agitation or irritability, seasonal affective disorder and pediatric depression; or bipolar disorders or manic depression, for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder; conduct disorder and disruptive behavior disorder; anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, for example, specific animal phobias, social anxiety, social

phobias, obsessive-compulsive disorder, stress disorders, including post-traumatic stress disorder and acute stress disorder, and generalized anxiety disorders; borderline personality disorder; schizophrenia and other psychotic disorders, for example, schizophreniform disorders, schizoaffective disorders, delusional disorders, brief psychotic disorders, shared
5 psychotic disorders, psychotic disorders with delusions or hallucinations, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder; mood disorders associated with psychotic disorders such as acute mania and depression associated with bipolar disorder, mood disorders associated with schizophrenia; behavioral disturbances associated with mental retardation, autistic disorder,
10 and conduct disorder in a mammal, including a human, comprising an amount of a compound according to claim 1 that is effective in treating such condition or disorder and a pharmaceutically acceptable carrier.

71. A pharmaceutical composition for treating a disorder or condition selected from the group consisting of delirium, dementia, and amnesic and other cognitive or
15 neurodegenerative disorders, such as Parkinson's disease (PD), Huntington's disease (HD), Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, memory disorder, vascular dementia, and other dementias, for example, due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple aetiologies; movement disorders such as akinesias, dyskinesias, including familial
20 paroxysmal dyskinesias, spasticities, Tourette's syndrome, Scott syndrome, PALSYS and akinetic-rigid syndrome; extra-pyramidal movement disorders such as medication-induced movement disorders, for example, neuroleptic-induced Parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia and medication-induced postural tremour; substance-
25 related disorders arising from the use of alcohol, amphetamines (or amphetamine-like substances) caffeine, cannabis, cocaine, hallucinogens, inhalants and aerosol propellants, nicotine, opioids, phenylglycidine derivatives, sedatives, hypnotics, and anxiolytics, which substance-related disorders include dependence and abuse, intoxication, withdrawal, intoxication delirium and withdrawal delirium; addictive behaviors such as gambling;
30 epilepsy; Down's syndrome; acute pain, chronic pain and migraine; demyelinating diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS), peripheral neuropathy, for example diabetic and chemotherapy-induced-neuropathy, and postherpetic neuralgia, trigeminal neuralgia, segmental or intercostal neuralgia and other neuralgias; and cerebral vascular disorders due to acute or chronic cerebrovascular damage such as cerebral
35 infarction, subarachnoid haemorrhage or cerebral oedema in a mammal, including a human, comprising an amount of a compound according to claim 1 that is effective in treating such condition or disorder and a pharmaceutically acceptable carrier.

72. A pharmaceutical composition for treating a disorder or condition selected from the group consisting of respiratory diseases, particularly those associated with excess mucus secretion, such as chronic obstructive airways disease, bronchopneumonia, chronic bronchitis, cystic fibrosis, adult respiratory distress syndrome, and bronchospasm; inflammatory diseases such as inflammatory bowel disease, psoriasis, Reiter's syndrome, Raynaud's syndrome, anarthropathies, fibrositis, osteoarthritis, rheumatoid arthritis, psoriatic arthritis, asthma, pruritis and sunburn; human immunodeficiency virus (HIV) infections; allergies such as eczema and rhinitis, and other allergies; hypersensitivity disorders such as poison ivy; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, and the like; ophthalmic conditions associated with cell proliferation such as proliferative vitreoretinopathy; cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis in a mammal, including a human, comprising an amount of a compound according to claim 1 that is effective in treating such condition or disorder and a pharmaceutically acceptable carrier.


73. A pharmaceutical composition for treating a disorder or condition selected from the group consisting of neoplasms, including breast tumours, gastric carcinomas, gastric lymphomas, neuroganglioblastomas and small cell carcinomas such as small cell lung cancer in a mammal, including a human, comprising an amount of a compound according to claim 1 that is effective in treating such condition or disorder and a pharmaceutically acceptable carrier.

74. A pharmaceutical composition for treating a disorder or condition selected from the group consisting of gastrointestinal (GI) disorders, including inflammatory gastrointestinal disorders such as inflammation bowel disease, disorders caused by *helicobacter pylori* and diseases of the GI tract such as gastritis, gastroduodenal ulcers, disorders associated with the neuronal control of viscera, ulcerative colitis, Crohn's disease, irritable bowel syndrome and emesis in a mammal, including a human, comprising an amount of a compound according to claim 1 that is effective in treating such condition or disorder and a pharmaceutically acceptable carrier.

75. A pharmaceutical composition for treating a disorder or condition selected from the group consisting of stress related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome; adverse immunological reactions such as rejection of transplanted tissues and disorders related to immune enhancement or suppression such as systemic lupus erythematosus; plasma extravasation resulting from cytokine chemotherapy; disorders of bladder function such as cystitis, bladder detrusor hyper-reflexia, inflammation of the urinary tract and incontinence, including urinary urge incontinence, overactive bladder, stress incontinence and mixed incontinence; fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; blood flow disorders caused by vasodilation and

vasospastic diseases such as angina and Reynaud's disease; angiogenesis; cardiovascular disorders; eating disorders, such as anorexia nervosa and bulimia nervosa; attention deficit hyperactivity disorder; chronic fatigue syndrome; sexual dysfunctions including premature ejaculation and male erectile dysfunction; premenstrual syndrome and premenstrual dysphoric disorder; fibromyalgia; and rheumatic diseases such as fibrositis in a mammal, including a human, comprising an amount of a compound according to claim 1 that is effective in treating such condition or disorder and a pharmaceutically acceptable carrier.

76. A compound of the formula



wherein Q is C=NH, C=CH₂, C=S, C=O, SO or SO₂;

each of Y and Z is N or CH, with the proviso that Y and Z can not both be N;

W is a one carbon linking group (i.e., methylene) or a saturated or unsaturated two or three carbon linking group, wherein each of the foregoing W groups can optionally be substituted with one substituent R⁷ or two substituents R⁷ and R⁶, or W is a one carbon linking group that forms, together with a 2, 3, 4 or 5 carbon chain, a 3, 4, 5 or 6 membered spiro ring, respectively;

or W is a saturated two carbon chain linking group that forms, together with a separate 1, 2 or 3 carbon chain, a fused 3, 4 or 5 membered ring, respectively;

or W is a saturated two carbon chain linking group, wherein one of the two carbons in the chain forms, together with a separate 2, 3, 4 or 5 carbon chain, a 3, 4, 5 or 6 membered spiro ring, respectively;

R⁵ and R⁸ are selected, independently, from hydrogen, -SO(C₁-C₆)alkyl, -SO₂-(C₁-C₆)alkyl, -SO-aryl, -SO₂-aryl, CF₃, halo, phenyl, phenyl-(C₁-C₂)alkyl, hydroxy, aryloxy, heteroaryloxy, pyridyl, tetrazolyl, oxazolyl, thiazolyl, (C₁-C₆)alkoxy optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, (C₁-C₆)alkyl optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, and (C₁-C₆)alkyl substituted with one or more substituents, preferably with from zero to two substituents selected, independently, from hydroxy, oxo, (C₁-C₆)alkoxy, phenyl-(C₁-C₃)alkoxy, phenyl, cyano, chloro, bromo, iodo, NR⁹R¹⁰, NR⁹COR¹⁰, NR⁹CO₂R¹⁰, CONR⁹R¹⁰, COR⁹ and CO₂R⁹;

R⁶ and R⁷ are selected, independently, from -SO(C₁-C₆)alkyl, -SO₂-(C₁-C₆)alkyl, -SO-aryl, -SO₂-aryl, CF₃, halo, phenyl, phenyl-(C₁-C₂)alkyl, hydroxy, aryloxy, heteroaryloxy, pyridyl, tetrazolyl, oxazolyl, thiazolyl, (C₁-C₆)alkoxy optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, (C₁-C₆)alkyl optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, and (C₁-C₆)alkyl substituted with one or more substituents, preferably with from zero to two substituents selected, independently, from hydroxy, oxo, (C₁-C₆)alkoxy, phenyl-(C₁-C₃)alkoxy, phenyl, cyano, chloro, bromo, iodo, NR⁹R¹⁰, NR⁹COR¹⁰, NR⁹CO₂R¹⁰, CONR⁹R¹⁰, COR⁹ and CO₂R⁹;

each R⁹ and each R¹⁰ is selected, independently, from hydrogen, (C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, phenyl and CF₃;

and wherein the phenyl groups in the definition of R⁵, R⁶, R⁷ and R⁸ and the phenyl moiety of phenyl (C₁-C₂)alkyl in the definition of R⁵, R⁶, R⁷ and R⁸ can optionally be substituted with one or more substituents, preferably with from zero to two substituents, that are selected, independently, from halo, hydroxy, (C₁-C₆)alkoxy optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, and (C₁-C₆)alkyl optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms; and

R¹⁴ is hydrogen, (C₁-C₆)alkyl or CF₃;

with the proviso that: (a) R⁸ can not be halo, hydroxy, cyano, aryloxy, heteroaryloxy, substituted or unsubstituted (C₁-C₆)alkoxy or methyl substituted with from 1-3 fluorine atoms; or a pharmaceutically acceptable salt thereof.

77. A compound according to claim 76, selected from the group consisting of:

5-Dimethoxymethyl-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

(1S,1aR)-5-Dimethoxymethyl-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

(1R,1aS)-5-Dimethoxymethyl-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-2-one;

6-Methoxy-3-methyl-2-oxo-1a,2,3,7b-tetrahydro-1H-3-aza-cyclopropa[a]naphthalene-5-carbaldehyde;

5 (1S,1aR)-6-Methoxy-3-methyl-2-oxo-1a,2,3,7b-tetrahydro-1H-3-aza-cyclopropa[a]naphthalene-5-carbaldehyde;

(1R,1aS)-6-Methoxy-3-methyl-2-oxo-1a,2,3,7b-tetrahydro-1H-3-aza-cyclopropa[a]naphthalene-5-carbaldehyde;

10 5-Methoxy-1,3,3-trimethyl-2-oxo-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-6-carbaldehyde;


6-Methoxy-1,3,3-trimethyl-2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde;

3-Methoxy-8-methyl-7-oxo-5,6,7,8-tetrahydro-[1,8]naphthyridine-2-carbaldehyde;

2-Methoxy-5-methyl-6-oxo-5,6,7,8-tetrahydro-[1,5]naphthyridine-3-carbaldehyde;

15 and pharmaceutically acceptable salts thereof.

78. A compound of the formula T-NH₂ wherein T-NH₂ is



and wherein p is zero, one or two;

20 R³ is selected from hydrogen, COR⁹, CO₂R⁹, optionally substituted phenyl, optionally substituted heterocyclic rings, and optionally substituted (C₁-C₈)alkyl wherein one of the CH₂ groups of said (C₁-C₈) alkyl may optionally be replaced with a sulfur, oxygen or carbonyl group and wherein said (C₁-C₈)alkyl can optionally be substituted with from one to three substituents, preferably with zero substituents or one substituent, independently selected from

25 hydroxy, oxo, phenyl-(C₁-C₃)alkoxy, phenyl, cyano, halo, optionally substituted heterocyclic rings, NR⁹COR¹⁰, NR⁹CO₂R¹⁰, CONR⁹R¹⁰, COR⁹, CO₂R⁹, NR⁹R¹⁰, and (C₁-C₆)alkoxy optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms;

and wherein the heterocyclic rings of R³ and the heterocyclic ring substituents on the

30 alkyl groups of R³ are selected, independently, from 3 to 7 membered saturated or unsaturated monocyclic rings containing from 1 to 4 ring heteroatoms, and 8 to 12 membered

saturated or unsaturated bicyclic rings containing from 1 to 4 ring heteroatoms, wherein said heteroatoms are selected, independently, from oxygen, nitrogen and sulfur, with the proviso that there can not be two adjacent ring oxygen atoms or two adjacent ring sulfur atoms in either the monocyclic or bicyclic heterocyclic rings, and with the proviso that heterocyclic rings
5 formed from NR^9R^{10} or $\text{CONR}^9\text{R}^{10}$ must contain at least one nitrogen atom;

and wherein the heterocyclic rings of R^3 and the heterocyclic ring substituents on the alkyl groups of R^3 can optionally be substituted with one or more substituents, preferably with zero, one or two substituents, independently selected from oxo, hydroxy, thioxo, halo, cyano, phenyl, $(\text{CH}_2)_m\text{NR}^9\text{R}^{10}$, $\text{NR}^9\text{COR}^{10}$, $(\text{CH}_2)_m\text{OR}^9$, wherein m is zero, one or two, and $(\text{C}_1\text{-C}_6)$ alkyl optionally substituted with one or more substituents, preferably with from zero to two substituents, independently selected from halo, CF_3 , methoxy and phenyl;
10

and wherein the phenyl groups of R^3 and the phenyl substituents in the alkyl groups of R^3 can optionally be substituted with one or more substituents, preferably with from zero to two substituents, independently selected from the group consisting of halo, cyano, nitro, CF_3 , $(\text{CH}_2)_m\text{NR}^9\text{R}^{10}$, wherein m is zero, one or two, $\text{NR}^9\text{COR}^{10}$, $\text{NR}^9\text{CO}_2\text{R}^{10}$, $\text{CONR}^9\text{R}^{10}$, $\text{CO}_2\text{NR}^9\text{R}^{10}$, COR^9 , CO_2R^9 , $(\text{C}_1\text{-C}_6)$ alkyl optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, $(\text{C}_1\text{-C}_6)$ alkoxy optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, and $(\text{C}_2\text{-C}_6)$ alkenyl optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms;
15
20

each of R^1 , R^2 , R^{11} , R^{12} and R^{13} are selected, independently, from hydrogen and $(\text{C}_1\text{-C}_6)$ alkyl optionally substituted with one or more substituents, preferably with zero, one or two substituents, that are selected, independently, from hydroxy, oxo, $(\text{C}_1\text{-C}_6)$ alkoxy and cyano;

or R^1 and R^2 , together with the carbon atoms to which they are attached, or R^2 and R^3 , together with the carbon and nitrogen to which they are attached, respectively, form a 5 or 6 membered saturated heterocyclic ring containing one or two heteroatoms that are selected, independently, from nitrogen, oxygen and sulfur, with the proviso that said ring can not contain two adjacent oxygen atoms or two adjacent sulfur atoms; or R^1 and R^2 , together with the carbons to which they are attached, form a 5 or 6 membered, saturated or unsaturated carbocyclic ring, and wherein said heterocyclic and carbocyclic rings formed by R^1 and R^2 or by R^2 and R^3 can be substituted with one or more substituents, preferably with zero substituents or one substituent, independently selected from halo, oxo, NR^9R^{10} , $(\text{C}_1\text{-C}_6)$ alkyl optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, and $(\text{C}_1\text{-C}_6)$ alkoxy optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms;
25
30
35

or R^{12} and R^{13} , together with the carbon atoms to which they are attached, form a 5 or 6 membered saturated heterocyclic ring containing one or two heteroatoms that are selected,

independently, from nitrogen, oxygen and sulfur, with the proviso that said ring can not contain two adjacent oxygen atoms or two adjacent sulfur atoms, or R^{12} and R^{13} , together with the carbons to which they are attached, form a 5 or 6 membered, saturated or unsaturated carbocyclic ring, and wherein said heterocyclic and carbocyclic rings formed by R^{12} and R^{13} can be substituted with one or more substituents, preferably with zero substituents or one substituent, independently selected from NR^9R^{10} , halo, phenyl-S-, phenyl-SO-, phenyl-SO₂-, oxo, (C₁-C₆)alkoxy optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, and (C₁-C₆)alkyl optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms:

10 with the proviso that no more than one of R^1 and R^2 , R^2 and R^3 , and R^{12} and R^{13} can form a ring;

R^4 is selected from phenyl, 2-, 3- or 4-pyridyl, 2- or 3-thienyl, and pyrimidyl, wherein R^4 can be optionally substituted with one or more substituents, preferably with zero or one substituent, selected, independently, from halo, (C₁-C₆)alkyl optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, (C₁-C₆)alkoxy optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms, and (C₂-C₆) alkenyl optionally substituted with from one to seven fluorine atoms, preferably with from zero to three fluorine atoms;

each R^9 and each R^{10} is selected, independently, from hydrogen, (C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, phenyl and CF₃;

or R^9 and R^{10} , when R^3 is NR^9R^{10} or $CONR^9R^{10}$, can form, together with the nitrogen to which they are attached, an optionally substituted heterocyclic ring that contains at least one nitrogen atom;

or a pharmaceutically acceptable salt thereof.

25 79. A compound according to claim 78, selected from the group consisting of:

6-Methyl-2-phenyl-piperidin-3-ylamine;

(2S,3S, 6S)-6-Methyl-2-phenyl-piperidin-3-ylamine;

(2R,3R, 6R)-6-Methyl-2-phenyl-piperidin-3-ylamine;

6-Ethyl-2-phenyl-piperidin-3-ylamine;

30 (2S,3S,6S)-6-Ethyl-2-phenyl-piperidin-3-ylamine;

(2R,3R,6R)-6-Ethyl-2-phenyl-piperidin-3-ylamine;

5-Methyl-2-phenyl-piperidin-3-ylamine;

5-Ethyl-2-phenyl-piperidin-3-ylamine;

5-propyl-2-phenyl-piperidin-3-ylamine;

35 5,5-diethyl-2-phenyl-piperidin-3-ylamine;

5,5-dimethyl-2-phenyl-piperidin-3-ylamine;

6,6-dimethyl-2-phenyl-piperidin-3-ylamine;

